Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE (Details Narrative)

v3.8.0.1
NOTES PAYABLE (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Aug. 15, 2016
Mar. 15, 2016
Jul. 07, 2014
Jun. 30, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Mar. 21, 2016
Notes payable balance         $ 172,748   $ 54,155
Unpaid balance             $ 942,596  
Unsecured promissory notes     $ 545,218          
Interest rate     12.00%          
Monthly payments     $ 10,658          
Common stock, shares issued         244,086,285 181,804,501    
Deposits applied as payment on note payable             $ 57,404  
Termination of licensing agreement         $ 132,804    
Original issuance discount         $ 11,250 11,250    
Loan [Member]                
Interest expense $ 17,970              
Common stock, shares issued 300,000              
Naltrexone Implant Formulation [Member]                
Interest expense           60,000    
Aggregate purchase price       $ 1,132,000   1,132,000    
Payment obligation           $ 1,000,000    
Period of obligation           14 months    
Licensing Agreements [Member]                
Termination of licensing agreement           $ 132,804    
Secured Promissory Note [Member]                
Secured promissory note   $ 360,000            
Issuance period   90 days            
Proceeds received   $ 300,000            
Original issuance discount   $ 60,000